Anti-viral activity of suramin against influenza A virus in A549 cells

---

Original Article

Author Details : Tanusri Nandi, Madhu Khanna*

Volume : 9, Issue : 3, Year : 2022

Article Page : 190-194

https://doi.org/10.18231/j.ijmr.2022.034

Suggest article by email

Get Permission

---

Abstract

Background and Objective: Influenza A virus (IAV) is highly contagious global factor of causing pandemics and epidemics occasionally. Suramin, an anti-trypanosomal drug, also under evaluation as anti-cancer and anti-viral agent. However, inhibitory effect of suramin against influenza A virus have not yet been explored. The purpose of this study was to investigate the anti-viral activity of suramin against IAV.
Materials and Methods: Cytotoxicity assay (IC) of suramin and oseltamivir was determined using MTT assay in A549 cells. The anti-viral effect of suramin was determined by RT-qPCR, western blot and CPE (Cytopathic effect). Oseltamivir, an antiviral drug that has established anti influenza activity was used as positive control drug.
Results: Half-maximal toxic concentration of suramin was found to be at 269.2 µg/ml (Log IC₅₀=2.43 µg/ml) and IC for oseltamivir was 145.4 µg/ml (Log IC₅₀=2.16 µg/ml) in A549 cells at 24hr. Suramin exhibited anti-viral activity at all the concentration, however at 250 µg/ml and 125 µg/ml demonstrated significant down regulation of viral RNA and protein in A549 cells. Oseltamivir, a positive control drug also showed significant viral inhibition at 200 and 100 µg/ml at 24hr.
Conclusion Suramin is effective in inhibiting influenza A virus replication in A549 cells at lower concentration.

Keywords: Suramin, Influenza a virus, Oseltamivir, Anti -viral.

How to cite : Nandi T, Khanna M, Anti-viral activity of suramin against influenza A virus in A549 cells. Indian J Microbiol Res 2022;9(3):190-194

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.